Dongcheng Pharmaceutical (002675.SZ): Jilin Changchun Nuclear Medicine Production Center put into operation.

Wisdom Finance and Economics APP news, Dongcheng Pharmaceutical (002675.SZ) announced that recently, the company received a notice from its wholly-owned subsidiary, Nanjing Jiangyuan Andyke Zheng Electronic Research and Development Co., Ltd. (hereinafter referred to as "Andyke"), notifying that it has received the "Radioactive Drug Production License" issued by the Jiangsu Provincial Drug Administration, adding a new Jilin Changchun Nuclear Medicine Production Center. The approval of this review marks that Andyke's Jilin Changchun Nuclear Medicine Production Center has met the requirements for production, and Andyke will add a new nuclear medicine production center. After the nuclear medicine production center is put into operation, it will be beneficial for Andyke to expand its market, increase sales revenue, and further improve the nationwide layout of nuclear medicine network construction.